PHREESIA INC (PHR) Stock Fundamental Analysis
NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock - Currency: USD
Overall PHR gets a fundamental rating of 4 out of 10. We evaluated PHR against 36 industry peers in the Health Care Technology industry. While PHR seems to be doing ok healthwise, there are quite some concerns on its profitability. PHR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHR has reported negative net income.
In the past year PHR had a positive cash flow from operations.
In the past 5 years PHR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
1.2 Ratios
PHR has a Return On Assets (-10.67%) which is comparable to the rest of the industry.
PHR's Return On Equity of -15.14% is fine compared to the rest of the industry. PHR outperforms 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a Gross Margin of 68.02%. This is in the better half of the industry: PHR outperforms 69.44% of its industry peers.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PHR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHR has more shares outstanding
PHR has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.27 indicates that PHR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.27, PHR belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
PHR has a debt to FCF ratio of 0.66. This is a very positive value and a sign of high solvency as it would only need 0.66 years to pay back of all of its debts.
PHR's Debt to FCF ratio of 0.66 is amongst the best of the industry. PHR outperforms 80.56% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that PHR is not too dependend on debt financing.
The Debt to Equity ratio of PHR (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Altman-Z | 6.27 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
PHR has a Current Ratio of 1.95. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
PHR has a Current ratio of 1.95. This is comparable to the rest of the industry: PHR outperforms 55.56% of its industry peers.
A Quick Ratio of 1.95 indicates that PHR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.95, PHR is in line with its industry, outperforming 58.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.65% over the past year.
PHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.29%.
Measured over the past years, PHR shows a very strong growth in Revenue. The Revenue has been growing by 27.46% on average per year.
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
3.2 Future
Based on estimates for the next years, PHR will show a very strong growth in Earnings Per Share. The EPS will grow by 55.21% on average per year.
The Revenue is expected to grow by 12.19% on average over the next years. This is quite good.
EPS Next Y77.81%
EPS Next 2Y49.05%
EPS Next 3Y55.21%
EPS Next 5YN/A
Revenue Next Year13.78%
Revenue Next 2Y12.67%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
PHR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 114.99 indicates a quite expensive valuation of PHR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHR is on the same level as its industry peers.
PHR is valuated expensively when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 114.99 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHR indicates a somewhat cheap valuation: PHR is cheaper than 61.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.51 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PHR's earnings are expected to grow with 55.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.05%
EPS Next 3Y55.21%
5. Dividend
5.1 Amount
No dividends for PHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.99
-0.63 (-2.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners99.8%
Inst Owner Change0.63%
Ins Owners5.25%
Ins Owner Change-2.84%
Market Cap1.55B
Analysts85.26
Price Target32.06 (23.36%)
Short Float %5.26%
Short Ratio5.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.24%
Min EPS beat(2)38.81%
Max EPS beat(2)41.66%
EPS beat(4)4
Avg EPS beat(4)25.79%
Min EPS beat(4)8.94%
Max EPS beat(4)41.66%
EPS beat(8)8
Avg EPS beat(8)25.32%
EPS beat(12)12
Avg EPS beat(12)23.1%
EPS beat(16)14
Avg EPS beat(16)4.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.24%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-0.59%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.12%
Revenue beat(12)6
Avg Revenue beat(12)0.6%
Revenue beat(16)10
Avg Revenue beat(16)1.9%
PT rev (1m)-2.62%
PT rev (3m)-1.57%
EPS NQ rev (1m)25.71%
EPS NQ rev (3m)28.08%
EPS NY rev (1m)0%
EPS NY rev (3m)22.75%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 114.99 | ||
| P/S | 3.56 | ||
| P/FCF | 70.51 | ||
| P/OCF | 32.23 | ||
| P/B | 5.48 | ||
| P/tB | 12.31 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.74
EYN/A
EPS(NY)0.23
Fwd EY0.87%
FCF(TTM)0.37
FCFY1.42%
OCF(TTM)0.81
OCFY3.1%
SpS7.31
BVpS4.75
TBVpS2.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 5.04% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.68% | ||
| Cap/Sales | 5.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | 6.27 |
F-Score7
WACC10.31%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y77.81%
EPS Next 2Y49.05%
EPS Next 3Y55.21%
EPS Next 5YN/A
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
Revenue Next Year13.78%
Revenue Next 2Y12.67%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
EBIT growth 1Y64.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year236.17%
EBIT Next 3Y64.73%
EBIT Next 5Y36.17%
FCF growth 1Y122.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y168.36%
OCF growth 3YN/A
OCF growth 5Y108.09%